Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark. Show more
Location: Dr. Neergaards Vej, Horsholm, 2970, Denmark | Website: https://evaxion.ai | Industry: Biotechnology | Sector: Healthcare
Market Cap
16.8M
52 Wk Range
$1.20 - $17.75
Previous Close
$2.58
Open
$2.77
Volume
366,420
Day Range
$2.54 - $2.85
Enterprise Value
659.1M
Cash
17.84M
Avg Qtr Burn
N/A
Insider Ownership
23.07%
Institutional Own.
7.09%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EVX-01 + pembrolizumab Details Melanoma | Phase 2 Data readout | |
EVX-02 Details Melanoma | Phase 1/2 Update |